Combined anti-VEGF and intravitreal dexamethasone treatment versus anti-VEGF alone for persistent diabetic macular edema: a comprehensive systematic review and meta-analysis.

We searched the PubMed, Embase, Cochrane, and Web of Science databases for studies that compared treatment with anti-vascular endothelial growth factor and dexamethasone to anti-vascular endothelial growth factor alone in patients with persistent diabetic macular edema.

The primary outcomes were changes in best corrected visual acuity, changes in central macular thickness, and the incidence of serious adverse events.

Of these 154 (48.88%) received anti-vascular endothelial growth factor alone, while 161 (51.12%) underwent combined therapy.